Sterile single-dose vial consists of dalbavancin hydrochloride powder equivalent to 500 mg of anhydrous dalbavancin, lactose monohydrate, and mannitol as excipients in it.
This drug is used in the treatment of various infections, such as skin structure-related infections and infections due to susceptible strains of bacteria such as Staphylococcus aureus and Streptococcus agalactia.
The observed side effects range from mild to moderate. They include fever, headache, hives, tachycardia, decreased appetite, cough, bleeding gums, pale skin, pinpoint red spots on the skin in a few cases, sore mouth, and stomach cramps.
To be prescribed cautiously in patients with a history of difficulty swallowing, infusion-related drug interactions, severe liver disorders, or renal dysfunction.
Dalbavancin is contraindicated in patients with a history of hypersensitivity. In cases of other severe allergic reactions in history.
Dosage and administration
In adults, the usual dose consists of once weekly via infusion with a loading dose of 1000 mg on day one followed by a 500 mg dose once weekly.
(We have also established roots and begun this new venture in other countries as well, such as Panama, Rwanda, Hawaii, Turkey, and Cape Verde.)